Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14636719 | 0.80 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL266354 | 0.77 | — | — | |
| SCHEMBL12512431 | 0.69 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL12496864 | 0.69 | PIK3CD (0.34) | MAPK1 | |
| SCHEMBL2728626 | 0.68 | P2RX7 (0.32) | — | |
| SCHEMBL2258059 | 0.68 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL17429089 | 0.68 | — | — | |
| SCHEMBL30790691 | 0.67 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL817040 | 0.67 | ALDH1A1 (0.33) | — | |
| SCHEMBL26983103 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674115-B2 | CRTH2 modulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674115-B2 | CRTH2 modulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674115-B2 | CRTH2 modulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130259830-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2516416-A1 | CRTH2 MODULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012009134-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011079007-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110150834-A1 | CRTH2 MODULATORS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2011-06-23 | — | — | US | disclosed |
| US-20110150834-A1 | CRTH2 MODULATORS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2011-06-23 | — | — | US | disclosed |
| US-5459260-A | In vivo stability | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0422596-B1 | Tricyclic carbapenem compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-07-05 | — | — | EP | disclosed |
| US-5393751-A | Antibiotics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-28 | — | — | US | disclosed |
| EP-0507313-A1 | Polycyclic carbapenem compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
| EP-0422596-A2 | Tricyclic carbapenem compounds | Takeda Chemical Industries, Ltd. (JP) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150834-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | MAPK1 1980/4885 |
| US-20130259830-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | MAPK1 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.